Open AccessComparison of the Efficacy and Safety between Doxycycline and Moxifloxacin in the Treatment of Tsutsugamushi Disease
Author(s) -
Qiang Qiu
Publication year - 2021
Publication title -
proceedings of anticancer research
Language(s) - English
Resource type - Journals
eISSN - 2208-3553
pISSN - 2208-3545
DOI - 10.26689/par.v5i5.2561
Subject(s) - doxycycline , moxifloxacin , medicine , group b , adverse effect , group a , incidence (geometry) , gastroenterology , clinical efficacy , liver function , clinical trial , surgery , antibiotics , microbiology and biotechnology , physics , optics , biology
Objective: To explore the efficacy and safety of doxycycline and moxifloxacin in the treatment of tsutsugamushi disease. Methods: There was a total of 80 cases of tsutsugamushi disease that were treated in Jiangsu Sihong Fenjinting Hospital from January 2017 to August 2020. The patients were divided into group A and group B, with 40 cases in each group. The patients in group A were treated with moxifloxacin whereas those in group B were treated with doxycycline. The efficacy and safety of the clinical treatment between the two groups were compared. Results: The effective rate was 72.5% in group A and 95.0% in group B. Compared with group A, group B was better (p < 0.05). The time taken for the resolution of clinical symptoms, the detection indexes of liver function, and the incidence of adverse reactions were also compared between the two groups, in which group B was significantly better than group A (p < 0.05). Conclusion: In the clinical treatment of tsutsugamushi disease, doxycycline has better therapeutic effect and higher safety compared to moxifloxacin. It can significantly improve the patient’s liver function, reduce the probability of adverse reactions, and accelerate the patient’s physical recovery.